Aryl sulfonic acids and derivatives as FSH antagonists

Details Aryl sulfonic acids and derivatives as FSH antagonists Aryl sulfonic acids and derivatives as FSH antagonists

2000-03-24

2002-03-12

Raymond, Richard L. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S238200, C514S252110, C514S227500, C514S445000, C514S709000, C514S408000, C514S316000

Reexamination Certificate

active

06355633

ABSTRACT:

BACKGROUND OF THE INVENTION
Reproduction in women depends upon the dynamic interaction of several compartments of the female reproductive system. The hypothalamic-pituitary unit orchestrates a series of events affecting the ovaries and the uterine-endometrial compartment which leads to the production of the ovum, ovulation, and ultimately appropriate conditions for fertilization. Specifically, hypothalamic hormones enhance the release of the gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). In the ovary, gonadotropins enhance the development of follicles which, in turn, secrete steroids (estradiol, progesterone) and peptides (inhibin, activin). Estradiol and inhibin levels progressively increase during the follicular phase of the menstrual cycle until ovulation. Afterwards, the follicular unit forms the corpus luteum which produces progesterone. Ovarian hormones, in turn, regulate the secretion of gonadotropins by establishing a classical long-loop negative feedback mechanism. The elucidation of these control mechanisms has provided opportunities for the development of effective strategies to control fertility, including both the enhancement of fertility and contraception. For recent reviews of FSH action see “FSH Action and Intraovarian Regulation”, B. C. J. M. Fauser, editor, Parthenon Publishing Group, 1997 and Hsueh, A. J., Bicsak, T., Jia, X.-C., Dahl, K. D., Fauser, B. C. J. M., Galway, A. B., Czwkala, N., Pavlou, S., Pakoff, H., Keene, J., Boime, I, “Granulosa Cells as Hormone Targets: The role of Biologically Active Follicle-Stimulating Hormone in Reproduction”
Rec. Prog. Horm. Res.,
1989, 45, 209-277.
Current hormonal contraception methods are steroidal and take advantage of long-loop feedback inhibition of gonadotropin secretion, as well as effecting peripheral mechanisms such as sperm migration and fertilization. An alternative strategy for hormonal contraception would be the development of specific antagonists of the receptor for FSH. Such antagonists would disrupt the actions of FSH on follicular development, thus producing the desired contraceptive effect. The utility of this strategy is supported by mechanism of infertility of women with resistant ovary syndrome. The infertility experienced by these women is the result of non-functional FSH receptors (K. Aittomaki, J. L. D. Lucena, P. Pakarinen, P. Sistonen, J. Tapanainnen, J. Gromoll, R. Kaskikari, E.-M. Sankila, H. Lehvaslaiho, A. R. Engel, E. Nieschlag, I. Huhtaniemi, A. de la Chapelle “Mutation in the Follicle-Stimulating Hormone Receptor Gene Causes Hereditary Hypergonadotropic Ovarian Failure”
Cell,
1995, 82, 959-968). This approach to contraception also appears applicable to men, since idiopathic male infertility seems related to a reduction in FSH binding sites. Moreover, men with selective FSH deficiency are oligo- or azoospermic with normal testosterone levels and present normal virilization. Therefore, orally active FSH antagonists may provide a versatile method of contraception.
Suramin Sodium, is an anticancer agent with a wide variety of activities. Recently suramin was shown to inhibit FSH binding to its receptor (Daugherty, R. L.; Cockett, A. T. K.; Schoen, S. R. and Sluss, P. M. “Suramin inhibits gonadotropon action in rat testis: implications for treatment of advanced prostate cancer”
J. Urol.
1992, 147, 727-732). This activity causes, at least in part, the decrease in testosterone production seen in rats and humans that were administered suramin (Danesi, R.; La Rocca, R. V.; Cooper, M. R.; Ricciardi, M. P.; Pellegrini, A.; Soldani, P.; Kragel, P. J.; Paparelli, A.; Del Tacca, M.; Myers, C. E, “Clinical and experimental evidence of inhibition of testosterone production by suramin.”
J. Clin. Endocrinol. Metab.
1996, 81, 2238-2246). Suramin is the only non-peptidic small molecule that has been reported to be an FSH receptor binding antagonist.
Compounds of formula A are described in the literature as follows:
Y. Yamashita [Yuki Gosei Kagaku Kyokai Shi (1970), 28(10), 1025-31] disclosed compounds of formula A (U, V, X, Y, Z=H) (U, V, Y, Z=H, X=p-NO
2
) (U, V, Y, Z=H, X=o-NO
2
) (U, V, Y, Z=H, X=p-OMe) (U, V, Y, Z=H, X=o-OMe) (U, V, Y, Z=H, X=p-Cl) (U, V, Y, Z=H, X=m-Cl) as fluorescent whitening agents.
Y. Yamashita [Yuki Gosei Kagaku Kyokai Shi (1971), 29(5), 519-25] disclosed a compound of formula A (U, V, Y, Z=H, X=o-Cl) as fluorescent whitening agents.
J. H. P. Tyman [J. Soc. Dyers Colour. (1965), 81, 102-104] disclosed a compound of formula A (U, V, Y, Z=H, X=p-CH
3
).
Yura et al. [Kogyo Kagaku Zasshi (1955) 58, 664-665; CA 1956; 11675] disclosed compounds of formula A (U, V, Y, Z=H, X=p-NHCH
3
) (U, V, Y, Z=H, X=p-NHCOCH
3
) (U, V, Y, Z=H, X=p-NHCOPh) (U, V, Y, Z=H, X=p-NHCH
2
OH).
D. W. Hein and E. S. Pierce [J. Am. Chem. Soc. 1954 (76) 2725-2730] disclosed compounds of formula A (U, V, Y, Z=H, X=o-OEt) (U, V, Y, Z=H, X=o-OPh) (U, V, Z=H, X=o-OMe, Y=p-OMe) (X, Y, Z=H, U=5-Cl, V=5′-Cl) (Y, Z=H, X=p-OMe,U=5-Cl, V=5′-Cl) (Y, Z=H, X=o-OEt, U=5-Cl, V=5′-Cl) (Y, Z=H, X=o-OPh, U=5-Cl, V=5′-Cl) (Z=H, X=o-OMe, Y=p-OMe, U=5-Cl, V=5′-Cl) (Y, Z=H, X=o-OEt, U=6-Cl, V=6′-Cl) (Z=H, X=o-OMe, Y=p-OMe, U=6-Cl, V=6′-Cl).
R. D. Haugwitz, L. Zalkow, E. Gruszecka-Kowalik and E Burgess (WO 9625399) disclosed compounds of formula A (U, V, Y, Z=H, X=o-OH) (U, V Z=H, X=p-NH
2
, Y=o-SO
3
H) (U, V, Z=H, X=p-NO
2
, Y=o-SO
3
H) (U, V=H, X=o-CO
2
H, Y=o-OH, Z=m-OH) (U, V Z=H, X=o-OH, Y=m-CH
2
SCH
2
CH
2
CO
0
H) for treatment of viral infections.
H. J. Roberts (U.S. Pat. No. 3453262) disclosed the compound of formula A (U, V, Z=H, X=p-OMe, Y=p-OMe) as a fluorescent brightening agent.
I. V. Aleksandrov and G. E. Samoliva [Deposited Publ. (1972), Issue VINITI 4341-72; CAN 85:32589] disclosed the compound of formula A (U, V, Y, Z=H, X=p-CN).
B. D. Gummow, G. A. F. Roberts [Makromol. Chem. (1986), 187(4), 995-1004] disclosed the compound of formula A (U, V, Y, Z=H, X=p-NH
2
).
A compound of formula A (U, V, Y, Z=H, X=m-NH
2
) was disclosed in DE 250342 (CA 6421-83-6; Beilstein 3526749).
F. Fleck [ Swiss 318,441 (1957)] disclosed compounds of formula A (U, V, Y, Z=H, X=o-OCH
2
CH═CHCH
3
) (U, V, Y, Z=H, X=m-OCH
2
CH═CHCH
3
) (U, V, Y, Z=H, X=o-OCH
2
CH=CH
2
) (U, V, Y, Z=H, X=p-OCH
2
CH═CH
2
) (U, V, Y, Z=H, X=m-OCH
2
CH═CH
2
).
R. Fleischhauer, F. Aldebert [Ger. 1,011,889 (1957)] disclosed compounds of formula A (U, V, Y, Z=H, X=p-OCH
2
C(CH
3
)=CH
2
) (U, V, Y, Z=H, X=m-OCH
2
C(CH
3
)═CH
2
).
M. Pestemer, A. Berger, A Wagner [Fachorgan Testilveredlung (1964), 19(6) 420-5] disclosed the compound of formula A (U, V, Z=H, X=o-OMe, Y=p-Me).
R. S. Long, A. K. Kantor [U.S. Pat. No. 2,848,484 (1958)] disclosed the compound of formula A (Z=H, X=o-OMe, Y=p-OMe, U=5-OMe, V=5′-OMe).
A. Mitrowsky, O. Bayer [Ger. 937,822 (1956)] disclosed the compound of formula A (U, V=H, X=o-OMe, Y=m-Me, Z=p-Me).
R. S. Long, A. K. Kantor [U.S. Pat. No. 2,841,613 (1958)] disclosed the compound of formula A (Z=H, X=o-OMe, Y=p-OMe, U=5-OMe, V=5′-Cl).
K. W. Eder [U.S. Pat. No. 2,806,054 (1957)&rsqb

Affiliated with

Also associated with

Rating

Aryl sulfonic acids and derivatives as FSH antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aryl sulfonic acids and derivatives as FSH antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl sulfonic acids and derivatives as FSH antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2839243